Tag: Ascensia Diabetes Care
Senseonics, Ascensia hit sweet spot
March 3, 2025HME News Staff
PARSIPPANY, N.J. – Senseonics Holdings and Ascensia Diabetes Care have integrated SweetSpot with the Eversense 365 Continuous Glucose Monitoring (CGM) System in the U.S., providing endocrinology practices that partner with them the ability to continue to improve patient care by seamlessly and regularly reviewing data from patients. SweetSpot combines a centralized software platform for managing diabetes device data with wrap-around clinical support services, including a virtual team...
Senseonics files for CE Mark
February 13, 2025HME News Staff
GERMANTOWN, Md. – Senseonics Holdings has filed for CE Mark registration for the Eversense 365 CGM system, paving the way for commercialization in European Union countries by Acensia Diabetes Care. “Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for patients in Europe,” said Tim Goodnow, president and CEO of Senseonics. “Given the success we have had to date with the U.S. launch, we look forward to the opportunity...
In brief: Hurricane waivers, NIV advocacy, CRT lobby
October 4, 2024HME News Staff
WASHINGTON – CMS will permit people with Medicare who have lost or had damage to their DMEPOS products because of Hurricane Helene to receive replacements of such items and services, according to a bulletin from AAHomecare.
Specifically, CMS waivers for Florida, Georgia, North Carolina, South Carolina, and Tennessee state that:
When DMEPOS is lost, destroyed, irreparably damaged, or otherwise rendered unusable, CMS is allowing DME MACs to have the flexibility to waive...
Ascensia launches Eversense 365
October 3, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care has launched its Eversense 365 continuous glucose monitoring system, which received clearance from the U.S. Food and Drug Administration in September. “Eversense offers a completely differentiated CGM experience, overcoming many of the frustrations experienced with traditional, short-term CGMs, such as early failure, disruptive false alerts and skin irritation,” said Brian Hansen, president of CGM at Ascensia. “With only one CGM replacement...
Senseonics, Ascensia launch one-year CGM system
September 17, 2024HME News Staff
GERMANTOWN, Md., and PARSIPPANY, N.J. – Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system. “The approval of Eversense 365 represents a significant leap in CGM innovation,” said Tim Goodnow, PhD, president and CEO of Senseonics. “Extending sensor longevity to a full year, coupled with seamless device connectivity and a high level of accuracy, provides...
In brief: UHC’s new capitated arrangement, NCPA’s cyberattack request
May 3, 2024HME News Staff
MINNEAPOLIS – UnitedHealthcare has entered into a capitated arrangement with Synapse Health for standard DME in Georgia and North Carolina for its Medicare Advantage plan members enrolled in HMO and PPO plans.
The change, announced on UHC’s website on May 1, is effective Aug. 1.
DME providers will need to join the Synapse Health network to continue to provide standard DME for these plan members. Synapse Health will reach out to providers with details about joining...
Ascensia receives iCGM designation for Eversense
May 1, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings have received an integrated CGM designation from the U.S. Food and Drug Administration. The designation indicates that the Eversense iCGM product can integrate with compatible medical devices, including insulin pumps. “Managing diabetes is all about personal choice and finding the options that best support an individual to live a healthier, less interrupted life,” said Brian Hansen, president of CGM at Ascensia. “For...
Health care goes OTC
April 26, 2024Theresa Flaherty, Managing Editor
As is par for the course these days, my inbox this month has been filled with diabetes tech announcements: Edgepark is adding a new insulin delivery system to its portfolio, Insulet’s Omnipod is fueling growth and Ascensia is expanding access to its Eversense device by extending its PASS program, which offers a substantial discount for users.
That last one is key: All the technology in the world won’t help if it’s too expensive for people to acquire. And this stuff is expensive...
In brief: OCR investigation, NHIA recommendations, SuperCare pilot
March 15, 2024HME News Staff
WASHINGTON – The Office of Civil Rights, which administers and enforces HIPAA private, security and breach notification rules, has announced that it will investigate the cyberattack on Change Healthcare to determine whether patient health information was compromised.
The agency will also investigate whether Change Healthcare and UnitedHealth Group were compliant with HIPAA rules.
“We are committed to ensuring access to care, while enforcing laws that bolster patient...
Ascensia extends PASS program
March 14, 2024HME News Staff
PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under...